NDA 021234 · Ibsa
Flector
Diclofenac Epolamine · Topical
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jan 31, 2007
Approved uses
2
Original approval plus efficacy supplements
Registered trials
11
3 Phase 3, 0 recruiting
FAERS reports
4,227
1,478 serious, 116 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history...
What it is approved for
From the label in effect Aug 24, 2026.
DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older. ( 1 )
Mechanism: Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 1, 2019 Supplement 16 · Efficacy LabelLetterPediatric Other
- Jan 31, 2007 Original approval · Type 2 - New Active Ingredient ReviewLabelLetter
1 products under this application
- FLECTOR · DICLOFENAC EPOLAMINE 1.3% · SYSTEM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Diclofenac Epolamine" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle SprainPivotal-lookingCompleted
Actavis Inc.Industry
NCT02324270 · 658 participants · Start May 2014 · Primary completion Dec 2014
Drug: Diclofenac epolamine · For: Ankle Sprain
Sites: Birmingham, Alabama; Goodyear, Arizona; Carlsbad, California · 31 sites in all
- Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the LimbsPivotal-lookingCompleted
Fidia Farmaceutici s.p.a.Industry
NCT04976088 · 214 participants · Start May 25, 2018 · Primary completion Oct 27, 2018
Drug: Diclofenac Sodium 140 mg medicated plaster; Diclofenac epolamine (DIEP) 180mg medicated plaster, Flector and 1 more · For: Trauma Injury; Inflammation
Sites: Gilching, Germany; Rheinbach, Germany; Budapest, Hungary · 16 sites in all
- Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP PancreatitisPivotal-lookingCompleted
Specialized Arab HospitalAcademic, hospital or other
NCT01946984 · 182 participants · Start Jun 2012 · Primary completion Jun 2013
Drug: Diclofenac hydroxyethylpyrrolidine; Normal Saline · For: Post-ERCP Acute Pancreatitis.
Sites: Nablus, Palestinian Territories
- Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue InjuryPivotal-lookingCompleted
IBSA Institut Biochimique SAIndustry
NCT05171673 · 151 participants · Start Oct 31, 2021 · Primary completion Jun 30, 2024
Drug: Licart™ (diclofenac epolamine) topical system · For: Soft Tissue Injuries
Sites: Little Rock, Arkansas; La Palma, California; DeLand, Florida · 11 sites in all
- Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back StrainCompleted
PfizerPfizer (PFE)
NCT01054820 · 123 participants · Start Jan 2010 · Primary completion Mar 2010
Drug: FLECTOR® Patch (diclofenac epolamine topical patch) 1.3% · For: Acute Back Strain
IBSA Institut Biochimique SAIndustry
NCT02132247 · 104 participants · Start May 2014 · Primary completion Oct 2016
Drug: Diclofenac hydroxyethylpyrrolidine · For: Athletic Injuries
Sites: Little Rock, Arkansas; St. Petersburg, Florida; Marietta, Georgia · 10 sites in all
Fidia Farmaceutici s.p.a.Industry
NCT04585321 · 52 participants · Start Nov 28, 2017 · Primary completion May 17, 2018
Drug: Diclofenac Sodium 140mg Medicated Plaster; Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac · For: Bioequivalence Study
Sites: Verona, Italy
Northwestern UniversityAcademic, hospital or other
NCT01380353 · 30 participants · Start Jun 2011 · Primary completion Nov 12, 2012
Drug: Diclofenac epolamine patch · For: Breast Cancer
Sites: Chicago, Illinois
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective648
- pain274
- drug hypersensitivity235
- nausea220
- off label use192
- headache176
- dizziness162
- rash156
- diarrhoea141
- malaise141
- fatigue140
- pruritus132
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 35 |
| 2009 | 43 |
| 2010 | 590 |
| 2011 | 164 |
| 2012 | 584 |
| 2013 | 260 |
| 2014 | 198 |
| 2015 | 224 |
| 2016 | 276 |
| 2017 | 231 |
| 2018 | 309 |
| 2019 | 379 |
| 2020 | 315 |
| 2021 | 204 |
| 2022 | 125 |
| 2023 | 85 |
| 2024 | 59 |
| 2025 | 98 |
| 2026 | 40 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Flector (Diclofenac Epolamine)
2024 spending
$1.7M
Beneficiaries
629
2,533 claims
Per beneficiary
$2,725
$10.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,582,318 |
| 2022 | $2,767,622 |
| 2023 | $2,379,946 |
| 2024 | $1,714,135 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical NSAIDs for acute musculoskeletal pain in adults.
Derry S, Moore RA, Gaskell H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews.
Derry S, Wiffen PJ, Kalso EA, et al. · Cochrane Database Syst Rev 2017 · Systematic Review
- Safety and Efficacy of the FLECTOR (Diclofenac Epolamine) Topical System in Children with Minor Soft Tissue Injuries: A Phase IV Non-randomized Clinical Trial.
Jones CA, Hoehler FK, Frangione V, et al. · Clin Drug Investig 2022 · Clinical Trial, Phase IV
- Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers.
Drago S, Imboden R, Schlatter P, et al. · Basic Clin Pharmacol Toxicol 2017 · Comparative Study, Randomized Controlled Trial
- Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
Kuehl K, Carr W, Yanchick J, et al. · Int J Sports Med 2011 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effectiveness and safety of diclofenac epolamine topical patch 1.3% for the treatment of acute pain due to back strain: an open-label, uncontrolled study.
Gimbel J, Jacobs D, Pixton G, et al. · Phys Sportsmed 2011 · Clinical Trial, Comparative Study
Sponsor: Ibsa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.